Cannasat Therapeutics Inc.

Cannasat Therapeutics Inc. (CTH: TSXV) is focused on the development of novel cannabinoid-based pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process.

Cannasat's pharmaceutical development strategy is to in-license proven drug delivery technologies and apply them to known cannabinoids to improve therapeutic efficacy while limiting side effects. Cannasat is adopting a low-risk development model by focusing on established technology platforms and applying them to well-characterized, known cannabinoid molecules. This strategy results in lower regulatory risk, shorter development timelines and significantly lower development costs.

Cannasat is currently working on two pre-clinical projects: CAT 310 and CAT 210. Cannasat’s lead product, CAT 310, utilizes patented drug delivery technology to deliver THC (dronabinol) systemically for rapid relief of neuropathic/chronic pain. Cannasat has completed proof-of-concept and early stage formulation development work for CAT 310 and is currently working on late-stage formulation scale-up in preparation for Phase I clinical trials.

CAT 210 is an early stage product that targets the treatment of neuropathic pain by localized delivery of cannabinoids.

David Hill, Chief Executive Officer
David Hill is the co-founder and CEO of Cannasat Therapeutics Inc. David is also a co-founder of Hill & Gertner Capital Corporation, a merchant bank specializing in early stage private and public company investments. David has a strong knowledge of the capital markets and has also co-founded two public companies for which he raised over $70 million.


Umar Syed, BSc. Pharm., MBA, Vice President, Scientific & Strategic Affairs
Umar Syed has nearly fifteen years of experience in the pharmaceutical and healthcare space. Umar has an MBA from the Richard Ivey School of Business, a B.Sc. (Pharmacy) from the University of Alberta, and over six years of clinical experience at The London Health Sciences Centre as a senior clinical pharmacist and advisor. Recently, he has worked in top-tier strategy consulting to the pharmaceutical and healthcare industries in New York, Boston, and Toronto as well as in Biotech Equity Research at BMO/Nesbitt Burns (“BMO”) in Toronto.

Cannasat Therapeutics Inc.
828 Richmond Street West
Toronto, Ontario, Canada
M6J 1C9
Phone: 416.703.2449
Fax: 416.703.8752
Email: info@cannasat.com

www.cannasat.com